Business
enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Ended the quarter with $39.1 million cash and investments on hand sufficient to fund operations, through the end of 2025, including potential PMA approval
About this update from Envveno Medical Corporation
[{"type":"text","content":"- Ended the quarter with $39.1 million cash and investments on hand sufficient to fund operations, through the end of 2025, including potential PMA approval of VenoValve®- Positive interim venous ulcer healing data showing significant improvement from the VenoValve pivotal trial presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting- Company on track to file application seeking VenoValve FDA approval in Q4 2024- Continued progress toward launch of GLP study for enVVe® transcatheter-based replacement venous valveIRVINE, CA / ACCESSWIRE / August 1, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) (\"enVVeno\" or the \"Company\"), a company setting new standards of care for the treatment of venous disease, today reported financial results for the second quarter 2024 and provided a corporate update. \"The past few months have been marked by a number of key data announcements from our SAVVE pivotal trial for the VenoValve. In addition to reporting a sustained clinically meaningful benefit as indicated by rVCSS for patients with an average 11-month period since receiving the VenoValve, we reported a significant improvement in venous ulcer healing for our most severe patients (C6). That data is especially impressive because all of these patients have failed conventional treatments, including many requiring years of wound care with poor results. Also important is that none of the patients with healed ulcers have experienced ulcer recurrences, putting an end to the vicious cycle often associated with conventional therapies,\" commented Robert Berman, CEO of enVVeno Medical. \"As we look toward the remainder of this year, we look forward to completing one-year visits for the full cohort of patients, filing our application seeking PMA approval from the FDA, and reporting the definitive data.\"Clinical Program HighlightsVenoValve: Surgical Replacement Venous ValvePositive interim venous ulcer healing data showing significant improvement from the VenoValve pivotal trial presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting:91% of venous ulcer patients evaluated at one year have either fully healed ulcers or ulcers that have improved.100% of venous ulcers with a duration of one year or less prior to VenoValve surgery have fully healed.89% of venous ulcers with a duration of more than one year prior to ...